Keith Flaherty

Keith Flaherty is Director of Clinical Research at the Massachusetts General Hospital Cancer Center and Professor of Medicine at Harvard Medical School.¹ He was previously a professor of medicine at the University of Pennsylvania. He is known for his research on targeted therapies for cancer, and in particular for his work on the melanoma drug vemurafenib.²³⁴⁵ In 2013, Massachusetts General Hospital partnered with AstraZeneca to partner Flaherty's research into developing a formula to identify vulnerabilities of tumors with AstraZeneca's library of drugs.⁶

References

Keith T. Flaherty, MD - Massachusetts General Hospital, Boston, MA
Target Cancer - A Roller Coaster Chase for a Cure - Series - NYTimes.com
Target Cancer - After Long Fight, Melanoma Drug Gives Sudden Reprieve - Series - NYTimes.com
Target Cancer - A Drug Trial Cycle - Recovery, Relapse, Reinvention - Series - NYTimes.com
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma — NEJM
Weintraub, Karen (19 May 2013). "MGH, AstraZeneca partner to create new drug combos". Boston Globe. Archived from the original on 8 April 2015. Retrieved 30 January 2015.

[1] Keith T. Flaherty, MD - Massachusetts General Hospital, Boston, MA

[2] Target Cancer - A Roller Coaster Chase for a Cure - Series - NYTimes.com

[3] Target Cancer - After Long Fight, Melanoma Drug Gives Sudden Reprieve - Series - NYTimes.com

[4] Target Cancer - A Drug Trial Cycle - Recovery, Relapse, Reinvention - Series - NYTimes.com

[5] Inhibition of Mutated, Activated BRAF in Metastatic Melanoma — NEJM

[6] Weintraub, Karen (19 May 2013). "MGH, AstraZeneca partner to create new drug combos". Boston Globe. Archived from the original on 8 April 2015. Retrieved 30 January 2015.

1

2

3

4

5

6